Stockreport

Inhibrx Biosciences Highlights 20% ORR for Ozekibart Combo in Late-Line Colorectal Cancer [Yahoo! Finance]

Inhibrx Biosciences, Inc.  (INBX) 
PDF Phase I/II data evaluating ozekibart in combination with FOLFIRI in a heavily pretreated population that company executives said has historically seen minimal benefit fr [Read more]